HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma

China Healthcare Weekly (Feb.19) - VBP on Biosimilar Drugs, Poor Performance of Healthcare Sector

Jinxin Fertility (1951.HK) - The New Policy, the Logic and the Risk Factors

InnoCare Pharma Ltd (9969.HK) - What Attracts Both Hillhouse and Vivo Capital?

Luye Pharma (2186.HK) - Could the Magic of Hillhouse Last Long?

JOINN Laboratories - Q3 Performance in Line with Expectations; Promising Globalization After HK IPO

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Joinn Laboratories China  Lt / Equity Capital Markets

<p>On January 31<sup>st</sup>,2021, <a href="https://www.smartkarma.com/entities/joinn-laboratories-china-co-a" target="_blank" data-smartkarma-citation="entities:28273:1" rel="noopener">Joinn Laboratories China Co-A (603127 CH)</a> successfully passed the listing hearing of HKEX, and will become the fourth CRO company with "A+H" listing after <a href="https://www.smartkarma.com/entities/pharmaron-beijing-co-ltd" target="_blank" data-smartkarma-citation="entities:28428:1" rel="noopener">Pharmaron Beijing Co Ltd-H (3759 HK),</a><a href="https://www.smartkarma.com/entities/wuxi-apptec-co-ltd-bf4a1265-beef-48b6-b82d-29308426030f" target="_blank" data-smartkarma-citation="entities:27795:1" rel="noopener">WuXi AppTec Co. Ltd. (2359 HK)</a> and <a href="https://www.smartkarma.com/entities/hangzhou-tigermed-consulting-co-ltd-1008d609-73bd-4d76-8315-b29502a448ff" target="_blank" data-smartkarma-citation="entities:29212:1" rel="noopener">Hangzhou Tigermed Consulting (H) (3347 HK)</a>, further enhancing its global influence while broadening its financing channels. Meanwhile, JOINN recently released the performance announcement in 2020. The net income attributed to shareholders in 2020 is expected to be RMB303 million to RMB322 million, up 69.9% to 80.3% YoY. Net income after deducting non-recurring gains and losses could reach RMB 275 million to RMB293 million, up 77.5% to 89.6% YoY. The performance beat the market expectations.</p>

On January 31st,2021, Joinn Laboratories China Co-A (603127 CH) successfully passed the listing hearing of HKEX, and will become the fourth CRO company with "A+H" listing after Pharmaron Beijing Co Ltd-H (3759 HK),WuXi AppTec Co. Ltd. (2359 HK) and Hangzhou Tigermed Consulting (H) (3347 HK), further enhancing its global influence while broadening its financing channels. Meanwhile, JOINN recently released the performance announcement in 2020. The net income attributed to shareholders in 2020 is expected to be RMB303 million to RMB322 million, up 69.9% to 80.3% YoY. Net income after deducting non-recurring gains and losses could reach RMB 275 million to RMB293 million, up 77.5% to 89.6% YoY. The performance beat the market expectations.

Hualan Biological Engineering (002007 CH)

Zhejiang Hisun Pharmaceutical Co, Ltd. (600267 CH)

Pre-IPO Joinn Laboratories - The Future Performance Is Worth Looking Forward To